YC-1: Dual-Action Soluble Guanylyl Cyclase Activator & HIF-1α Inhibitor for Cancer and Hypoxia Research

Executive Summary: YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol is a small-molecule tool compound widely used for its dual functionality as a soluble guanylyl cyclase (sGC) activator and hypoxia-inducible factor-1α (HIF-1α) inhibitor [APExBIO product page]. It post-transcriptionally inhibits HIF-1α, blocking hypoxia-driven gene expression in tumor models (Zhou et al., 2025). YC-1 reduces tumor angiogenesis and growth in vivo by interfering with the oxygen-sensing pathway. It acts as an inhibitor of platelet aggregation and vascular contraction, making it relevant in circulation disorder studies. The compound is DMSO- and ethanol-soluble, with high purity and suitability for research use only.

Biological Rationale

Tumor microenvironments are typically hypoxic, leading to stabilization and activation of HIF-1α, a transcription factor central to the hypoxia signaling and oxygen-sensing pathway [DOI]. HIF-1α upregulates genes promoting angiogenesis (e.g., VEGF), glycolysis, and cell survival, supporting tumor growth and metastasis. Soluble guanylyl cyclase (sGC) is another critical enzyme, mediating nitric oxide (NO)-dependent cyclic GMP (cGMP) signaling, which influences vascular tone, platelet function, and cell proliferation. Dysregulation of these pathways contributes to tumor progression, metastasis, apoptosis resistance, and vascular disorders. Targeting both HIF-1α and sGC provides a multifaceted strategy for dissecting cancer biology, hypoxia adaptation, and circulatory dysfunction. YC-1, supplied by APExBIO, was developed to exploit these mechanistic intersections for research.

Mechanism of Action of YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol

YC-1 exerts its effects via two primary mechanisms:

1. HIF-1α Inhibition: YC-1 suppresses post-transcriptional accumulation and nuclear translocation of HIF-1α under hypoxic conditions, thereby preventing transcriptional activation of hypoxia-responsive genes such as VEGF, GLUT1, and BNIP3L. This effect is prominent in hepatoma and other solid tumor cell lines (Zhou et al., 2025).
2. Activation of Soluble Guanylyl Cyclase: Independently of nitric oxide, YC-1 directly stimulates sGC, increasing intracellular cGMP. This leads to inhibition of platelet aggregation, relaxation of vascular smooth muscle, and modulation of cellular signaling relevant to circulation and vascular research [APExBIO].

These effects converge to inhibit tumor angiogenesis, promote apoptosis, and modulate vascular and platelet responses. Recent data also suggest YC-1 can disrupt the HIF-1α/BNIP3L mitophagy axis, impacting mitochondrial quality control in hypoxic tissues [Zhou et al., 2025]. For a detailed mechanistic breakdown, see our comparative analysis (contrast: this article provides updated benchmark data on mitochondrial impacts beyond the prior mechanistic review).

Evidence & Benchmarks

• YC-1 inhibits hypoxia-induced HIF-1α protein accumulation in hepatoma cells within 1–6 hours of exposure at 10–50 μM concentrations (Zhou et al., 2025, DOI).
• In vivo, YC-1 reduces tumor size and vascularization in xenograft mouse models, with statistical significance at doses ≥10 mg/kg/day (Zhou et al., 2025, DOI).
• YC-1-treated tumors display reduced expression of HIF-1α and HIF-1 target genes (e.g., VEGF, GLUT1) compared to vehicle controls (Zhou et al., 2025, DOI).
• YC-1 activates sGC and increases cGMP levels, inhibiting platelet aggregation and vascular contraction in isolated tissues in vitro (APExBIO, product page).
• YC-1 is soluble at ≥30.4 mg/mL in DMSO and ≥16.2 mg/mL in ethanol, but insoluble in water (APExBIO, product sheet).
• For further comparative application data, see YC-1: Soluble Guanylyl Cyclase Activator for Cancer Research (contrast: this article includes more recent in vivo benchmarks and practical solubility data).

Applications, Limits & Misconceptions

Applications:

• Investigation of HIF-1 signaling and hypoxia-induced gene expression in cancer and vascular models.
• Study of sGC/cGMP pathway modulation in circulation disorder, platelet function, and vascular biology.
• Functional dissection of tumor angiogenesis and mitochondrial quality control mechanisms under hypoxic stress.
• Research into apoptosis, tumor growth inhibition, and metastasis blockade.
• Advanced workflow integration in translational cancer and hypoxia pathway research (contrast: this article adds dose/solubility parameters and practical pitfalls not covered previously).

YC-1 is intended for research use only. It is not for diagnostic or medical purposes. The compound’s effects are most pronounced in hypoxic or pathologically stressed cells/tissues, with limited impact in normoxic, non-stressed systems.

Common Pitfalls or Misconceptions

• YC-1’s inhibitory effects on HIF-1α are post-transcriptional; it does not block HIF1A gene transcription.
• Compound is insoluble in water; improper solvent selection leads to precipitation or loss of activity.
• YC-1 is not approved for clinical/therapeutic use and should not be used in humans or animals outside research protocols.
• Some effects (e.g., cGMP elevation) are cell-type and context dependent; not all cell lines respond equally.
• Long-term storage of YC-1 solutions in DMSO or ethanol reduces purity and potency; prepare fresh aliquots when possible.

Workflow Integration & Parameters

YC-1 is supplied by APExBIO (SKU: B7641) at >98% purity. It is soluble at ≥30.4 mg/mL in DMSO and ≥16.2 mg/mL in ethanol. Stock solutions should be prepared in these solvents, aliquoted, and stored at room temperature for short-term use. Avoid repeated freeze-thaw cycles and long-term storage of diluted solutions. For in vitro assays, typical working concentrations range from 1–100 μM, depending on cell type and endpoint. For in vivo studies, published doses span 2–50 mg/kg/day via intraperitoneal injection in mouse models.

YC-1’s dual-action profile enables its use in parallel hypoxia signaling and cGMP pathway assays. Benchmarks recommend careful titration for cell line- or tissue-specific optimization. For troubleshooting and advanced protocol guidance, see YC-1: Mechanistic Roadmap (contrast: this piece adds up-to-date workflow and solubility recommendations beyond the prior strategic roadmap).

Conclusion & Outlook

YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol provides a rigorously validated tool for dissecting hypoxia signaling, HIF-1α biology, and cGMP-mediated processes in cancer and vascular research. Its dual action as a HIF-1α inhibitor and soluble guanylyl cyclase activator sets it apart for translational and mechanistic studies. As new research explores mitochondrial and neuroprotective axes influenced by HIF-1α (Zhou et al., 2025), YC-1’s role as a benchmark compound is likely to expand. For detailed specifications or to order, visit the YC-1 product page at APExBIO.